Neal Shiv Chawla, Luke Kuttschreuter, Kamlesh Kumar Sankhala, Sarah Benafif, Louise Carter, Nicholas Coupe, T.R. Jeffry Evans, Timothy Guy Humphries, Steven Chuan-Hao Kao, Harriet S. Walter, Andy Karabajakian, Alexandre Grimaldi, Caroline Hoffmann, Gill Low, Andrew Pierce, Stephane Champiat. "INVOKE: A phase 1 study of OKN4395, a first-in-class EP2/EP4/DP1 triple prostanoid receptor antagonist, in patients with advanced solid tumors.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.tps2683